Project Grant R43HL154868

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded Novomedix LLC a $306,872 Project Grant to develop and commercialize a novel, safer, and more effective therapy for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive pulmonary fibrosis conditions. Novomedix has developed a series of small molecule compounds that inhibit myofibroblast activation and differentiation, potentially reversing fibrotic...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...

This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $350,000 in funding to Adiutrix Therapeutics LLC to develop a novel anti-fibrotic compound platform. The goal is to identify and develop first-in-class therapeutics that target the collagen prolyl-4 hydroxylase (C-P4H) enzyme, which plays a critical role in the maturation of collagen and fibrosis in diseases such as idiopathic pulmonary fibrosis (IPF), scleroderma, and chronic kidney...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $356,250 to Vasarya Therapeutics, Inc. to develop a novel drug candidate for the treatment of idiopathic pulmonary fibrosis (IPF). The award will support a two-phase research project to perform affinity maturation and liability assessment, and then establish a primary drug candidate through further preclinical evaluation,...

This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports research on a peptide derived from collagen XVIII that has demonstrated anti-fibrotic effects in preclinical models of lung fibrosis. The goal is to assess the therapeutic potential of this peptide in a murine model of lung fibrosis, identify the minimal effective dose and optimal dosing frequency, and conduct...

This federal Project Grant award of $1,193,262 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to advance the development of an adeno-associated virus-mediated SGPL1 gene therapy as a novel treatment for idiopathic pulmonary fibrosis (IPF). The research will focus on validating the efficacy of this gene therapy approach in preclinical IPF models and optimizing its delivery methods. The ultimate goal is to...

Novelmed Therapeutics, Inc. was awarded a $1,599,495 Project Grant from the National Heart, Lung and Blood Institute of the Department of Health and Human Services. The grant falls under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. Novelmed will use the funding to develop a novel disease-modifying treatment for paroxysmal nocturnal hemoglobinuria (PNH). The company's lead drug candidate selectively inhibits the alternative pathway of...

This federal Project Grant award of $1,410,668.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of cyclin-dependent kinase 9 (CDK9) in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The primary objectives are to elucidate the molecular mechanisms by which CDK9 regulates IPF, screen CDK9 inhibitors for their effectiveness against fibrosis, and test the therapeutic potential of...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $604,115 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop and evaluate advanced imaging technologies for predicting progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease. The key products and services to be delivered include: 1)...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $805,845 to the Proteogenomics Research Institute for Systems Medicine to develop and test a novel lung precision drug delivery system (LPDDS) targeting lung myofibroblasts to treat lung fibrosis. The goal is to create "dual precision" bispecific therapeutics that can actively transport anti-fibrotic agents directly...